Ankush Sharma

SrScientist 👨🏽‍💻|multi-omics | haem-onco |ScientistonQwerty #Az Perfecting the art of making Indian masala Chai ☕️ ¯\_(ツ)_/¯

[Ankush Sharma @ankushoriginal]

@vfsglobalcare Dear @vfsglobalcare care to reply after 2 days ??

[Ankush Sharma @ankushoriginal]

.@MEABharat Why renewal of passports in Australia takes time that too more than 3 months ? Posting on behalf of a friend ! @VFSGlobal takes more than a month to forward the applications !! Its high level of incompetence and brings more uncertainty for travel plans !

[Ankush Sharma @ankushoriginal]

@nopra_shant Can everyone get a connection in @MEABharat @HCICanberra ??

[Ankush Sharma @ankushoriginal]

@sardesairajdeep @sanjaymanjrekar Reverse hypothetically ! No T20 worldcup for India , then you would hv thouht the same way , start giving credit to yourselves , you are living in much better India than you were grown into . Its not just cricket !

[Ankush Sharma @ankushoriginal]

@sardesairajdeep @sanjaymanjrekar It is just that Having things in abundance often feels unimportant because human psychology is wired to assign value based on scarcity, utility, and novelty! Your mentality is getting shaped like this coz India is now winning more frequent as opposed to your times …

[Oscar Tahuahua @OscarTahuahua]

More evidence that #immunotherapy works better in the morning.

In a prospective, randomized phase III trial, giving first-line chemo-immunotherapy earlier in the day (<15:00) nearly doubled PFS (11.3 vs 5.7 mo, HR 0.40) and improved OS (28.0 vs 16.8 mo; HR 0.42) in advanced NSCLC.

More effective, no added cost and easy to implement.
Likely reflects circadian immune rhythms with greater CD8⁺ activation and less T-cell exhaustion.
https://t.co/q4JrFU4yws @OncoAlert

[Ankush Sharma @ankushoriginal]

@aiims_newdelhi The link attached points to story of miley brown

[Ankush Sharma @ankushoriginal]

@airindia Indeed they are without the policies or knowhow what to do !

Whats the solution for travelers traveling zurich - delhi - udaipur. ( with infant ) and how much time one should take to resolve the problem ?

[David Russler-Germain, MD/PhD @dgermain21]

The implications of these PFS data are huge given this was time limited therapy. If in remission around 1 year, you probably have at least a 50/50 chance of remaining in remission 4 years later off therapy! If this is what we see in 3L+, could anti-CD3xCD20 BsAbs be curative therapies for FL?

[David Russler-Germain, MD/PhD @dgermain21]

Yup, I'm aware :)

And also, for comparison:

https://t.co/iV9APUhPzv

[Dr Rishabh Jain @DrRishabhOnco]

CRC before 50 isn’t just early - it’s different at the core 🧬🔥

📊 Large NGS study (n=1209; 4 Italian centers):

• EO-CRC (≤50y; n=298) vs AO-CRC (n=911)

• Profiling with FoundationOne CDx (324 genes)

🔍 Molecular fingerprints in EO-CRC:

📈 Amplifications: MYC, RAD21, GNAS, MAPK1

❌ Loss: CDKN2B

🧪 Mutations: APC R876*, NRAS Q61L, PIK3CA E545K, TP53 G266V

⏳ Survival impact (PSM analysis):

📉 OS → 35 vs 41 mo (P=0.0326)

💪 ECOG 0 → 35 vs 44 mo (P=0.0026)

⚡ RAS/BRAF-mut → 27 vs 44 mo (P=0.0024)

⚖️ Take-home: EO-CRC is biologically distinct, molecularly aggressive, and demands age-tailored strategies.

Pretta et al. ESMO Open 2025. DOI: https://t.co/SS91xPcFPA

#ColorectalCancer #OncoTwitter #MedTwitter
@OncoAlert @oncodaily @asco @esmo
@myesmo

[Dr Rishabh Jain @DrRishabhOnco]

Not just coffee - even pembrolizumab works better before 11 AM ☕💉

📊 Eur J Cancer 2025 | 9-center retrospective | n=450
1L Pembrolizumab monotherapy in advanced NSCLC

Timing groups:
🌅 Early ≤11:00 AM
🌙 Late >11:00 AM

Results (PSM, n=206 | median f/u 62.5 mo):
•OS: 43.7 vs 32.4 mo ➝ HR 0.67 (95% CI 0.46–0.97, p=0.03) ✅

•PFS: 13.8 vs 11.6 mo ➝ NS (HR 0.80)

•irAEs ≥G3: 26.2% vs 13.6% (p=0.04) ⚠️

✨ Take-home:
First-dose timing may prime immune activation.
Morning infusion → better OS, but higher severe irAEs.
A simple, low-cost tweak worth prospective testing.

🔗 Eur J Cancer 2025
DOI: 10.1016/j.ejca.2025.115748
Full text: https://t.co/d4b8yWcHc0

#LungCancer #Immunotherapy #Chronotherapy #OncoTwitter
@OncoAlert @OncoDailyNet
@oncodaily @myesmo @asco

[Ming "Tommy" Tang @tangming2005]

Nature methods:
Co-profiling of in situ RNA-protein interactions and transcriptome in single cells and tissues
https://t.co/P6GFcDcCfP

[Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD]

🧵🧵 Daratumumab-based triplets in RRMM: Real-world DPd vs DKd outcomes @USMIRCNEWS #USMIRC

1/ 💉 Study design: Multicenter retrospective analysis (n=399) of RRMM patients:
•DPd = Dara + Pomalidomide + Dex (n=295)
•DKd = Dara + Carfilzomib + Dex (n=104)
Goal 👉 compare efficacy & safety outside trial setting.

#ICE_T #mmsm #MedEd #myeloma #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما

[Naseema Gangat @n_gangat]

Rx of unfit patients with AML: Keeping up with the recent advances #amlsm
https://t.co/PdjJz195WN

[Vincent Rajkumar @VincentRK]

Academic medicine is bleeding talent. The best experts are counting to retire or switch careers at an alarming rate.

It’s folly to think that you can replace top talent easily — you will need 10 people to provide the level of productivity of one top talent.

The effects may not seem obvious. Because you seldom miss what you didn’t know you could achieve. But it will happen.
In patient care, in research, and in the development of new treatments.

[Vincent Rajkumar @VincentRK]

Just out: Current Treatment Algorithm — completely open access — for elderly patients with acute myeloid leukemia. AML. @BloodCancerJnl

By @n_gangat @MayoClinic &amp;
Dr. Courtney Dinardo @MDAndersonNews
Link: https://t.co/wYjHOzEJfS

[Ankush Sharma @ankushoriginal]

Zincore uses a completely new method to help proteins bind better to DNA. We gave the protein pair the name Zincore because it controls an important group of switches known as ‘zinc fingers.| Science https://t.co/WO5s9f7sjU

[Michael Dickinson @mike_dickinson1]

Two comprehensive reviews on new bispecific antibodies in #lymphoma made pretty and online @Haematologica #lymsm @AdrianMinson @nancybartlettMD